Literature DB >> 14713271

Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature.

G Minniti1, M-L Jaffrain-Rea, V Esposito, A Santoro, G Tamburrano, G Cantore.   

Abstract

Criteria to define the biochemical remission of acromegaly following surgery have changed over the years, and the current use of stringent criteria needs a critical re-evaluation of the surgical results. On the other hand, few data are currently available concerning the possible impact of pituitary surgery on the quality of life of operated acromegalic patients. In this prospective study, we wished to evaluate the initial outcome and long-term recurrence rate in a large series of acromegalic patients operated on by transsphenoidal surgery (TSS), to carefully analyse predictive factors for surgical outcome and to point out possible additional effects of surgery in these patients. Ninety-two out of 98 operated patients could be considered for follow-up. Biochemical remission was strictly defined as plasma GH levels <1 ng/ml during an oral glucose tolerance test (OGTT) and normalisation of age-related IGF-I levels. Hormonal assessment, including an OGTT, was performed 6 months following surgery and then annually to evaluate pituitary function. Fifty-five per cent of patients achieved a biochemical remission of acromegaly. The remission rate at 6 months was 80% for patients with microadenoma and 50% for macroadenoma. Univariate analysis showed that a large extrasellar extension, preoperative high GH levels and dural invasion were correlated with a poor outcome of surgery while, according to multivariate analysis, only invasion of cavernous sinus and preoperative GH levels > 10 ng/ml were independent negative predictors. Mortality was 0% and the overall complication rate was about 10%. Pituitary function worsened in five patients but improved in 16 out of 30 patients with preoperative pituitary defects. No recurrence was observed during a median follow-up of about 8 years. We conclude that TSS is able to achieve a biochemical remission in more than half of acromegalic patients, and that the current criteria for remission seem to indicate a cure in most cases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14713271     DOI: 10.1677/erc.0.0100611

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  21 in total

1.  Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.

Authors:  Claudia Pivonello; Roberta Patalano; Domenico Solari; Renata S Auriemma; Federico Frio; Francesca Vitulli; Ludovica F S Grasso; Marialuisa Di Cera; Maria Cristina De Martino; Luigi M Cavallo; Paolo Cappabianca; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2018-07-31       Impact factor: 3.633

Review 2.  Management of aggressive growth hormone secreting pituitary adenomas.

Authors:  Daniel A Donoho; Namrata Bose; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

3.  Predictive model of surgical remission in acromegaly: age, presurgical GH levels and Knosp grade as the best predictors of surgical remission.

Authors:  M Araujo-Castro; E Pascual-Corrales; V Martínez-Vaello; G Baonza Saiz; J Quiñones de Silva; A Acitores Cancela; A M García Cano; V Rodríguez Berrocal
Journal:  J Endocrinol Invest       Date:  2020-05-21       Impact factor: 4.256

Review 4.  Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies.

Authors:  Jennifer C Stone; Justin Clark; Ross Cuneo; Anthony W Russell; Suhail A R Doi
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

5.  Predictors of postoperative biochemical remission in acromegaly.

Authors:  Shun Yao; Wen-Li Chen; Sherwin Tavakol; Farhana Akter; Michael P Catalino; Xiaopeng Guo; Jie Luo; Ai-Liang Zeng; Leo Zekelman; Zhi-Gang Mao; Yong-Hong Zhu; Qing-Zhi Wu; Edward R Laws; Wenya Linda Bi; Hai-Jun Wang
Journal:  J Neurooncol       Date:  2021-01-04       Impact factor: 4.130

6.  Surgical results of growth hormone-secreting pituitary adenoma.

Authors:  Min-Su Kim; Hyun-Dong Jang; Oh-Lyong Kim
Journal:  J Korean Neurosurg Soc       Date:  2009-05-31

Review 7.  Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?

Authors:  Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2009-02-18       Impact factor: 3.478

Review 8.  Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly.

Authors:  Laure Cazabat; Jean-Claude Souberbielle; Philippe Chanson
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 9.  Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.

Authors:  Mehdi Zeinalizadeh; Zohreh Habibi; Juan C Fernandez-Miranda; Paul A Gardner; Steven P Hodak; Sue M Challinor
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

10.  Remission of acromegaly following long-term therapy with cabergoline: report of two cases.

Authors:  Johan A Verhelst; Pascale J Abrams; Roger Abs
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.